OPG/RANKL/RANK pathway as a therapeutic target in cancer

Research output: Contribution to journalArticle

Standard

OPG/RANKL/RANK pathway as a therapeutic target in cancer. / McGrath, Emmet.

In: Journal of Thoracic Oncology, Vol. 6, No. 9, 01.09.2011, p. 1468-73.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{8f9b1e984a6045e2b3fcfbe5e96d9555,
title = "OPG/RANKL/RANK pathway as a therapeutic target in cancer",
abstract = "Bone metastases play an important role in the morbidity and mortality of patients with malignant disease. Despite therapeutic advances in the treatment of solid organ malignancy such as lung cancer, less development on metastasis interventions has been forthcoming. More recent research has focused on molecular pathway manipulation in the prevention and treatment of metastatic bone disease and associated complications such as bone pain and hypercalcemia. The osteoprotegerin/receptor activator of nuclear factor-кβ ligand/receptor activator of nuclear factor-кβ pathway, which is physiologically involved in bone turnover, has been of considerable interest, and recent promising data have been revealed. In this study, we describe this molecular pathway in terms of its natural physiological function, manipulation for therapeutic benefit, and recent clinical trial results.",
author = "Emmet McGrath",
year = "2011",
month = sep,
day = "1",
doi = "10.1097/JTO.0b013e318229421f",
language = "English",
volume = "6",
pages = "1468--73",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

RIS

TY - JOUR

T1 - OPG/RANKL/RANK pathway as a therapeutic target in cancer

AU - McGrath, Emmet

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Bone metastases play an important role in the morbidity and mortality of patients with malignant disease. Despite therapeutic advances in the treatment of solid organ malignancy such as lung cancer, less development on metastasis interventions has been forthcoming. More recent research has focused on molecular pathway manipulation in the prevention and treatment of metastatic bone disease and associated complications such as bone pain and hypercalcemia. The osteoprotegerin/receptor activator of nuclear factor-кβ ligand/receptor activator of nuclear factor-кβ pathway, which is physiologically involved in bone turnover, has been of considerable interest, and recent promising data have been revealed. In this study, we describe this molecular pathway in terms of its natural physiological function, manipulation for therapeutic benefit, and recent clinical trial results.

AB - Bone metastases play an important role in the morbidity and mortality of patients with malignant disease. Despite therapeutic advances in the treatment of solid organ malignancy such as lung cancer, less development on metastasis interventions has been forthcoming. More recent research has focused on molecular pathway manipulation in the prevention and treatment of metastatic bone disease and associated complications such as bone pain and hypercalcemia. The osteoprotegerin/receptor activator of nuclear factor-кβ ligand/receptor activator of nuclear factor-кβ pathway, which is physiologically involved in bone turnover, has been of considerable interest, and recent promising data have been revealed. In this study, we describe this molecular pathway in terms of its natural physiological function, manipulation for therapeutic benefit, and recent clinical trial results.

U2 - 10.1097/JTO.0b013e318229421f

DO - 10.1097/JTO.0b013e318229421f

M3 - Article

C2 - 21849854

VL - 6

SP - 1468

EP - 1473

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 9

ER -